2.A 59-year-old Irish-American woman is diagnosed with metastatic cutaneous melanoma. After discussion at a multidisciplinary conference, the patient is deemed not to be a cand idate for surgical metastasectomy. The recommendation is for systemic treatment. Molecular analysis of the tumor reveals a BRAF V600E mutation. She is not interested in immunotherapy. Which of the following is the next best step?

A. Interferon alpha

B. Cisplatin, vinblastine, dacarbazine

C. Dabrafenib plus trametinib

D. Observation